VioQuest Appoints Michael D. Becker as President and Chief Executive Officer

    BASKING RIDGE, N.J., Nov. 14 /PRNewswire-FirstCall/ -- VioQuest
 Pharmaceuticals (OTC Bulletin Board: VQPH) a biopharmaceutical company
 focused on developing cancer therapeutics, today announced the appointment
 of Michael D. Becker as President and Chief Executive Officer, effective
 November 21, 2007. Mr. Becker has also been appointed to the Company's
 Board of Directors.
     Mr. Becker joins VioQuest from Cytogen Corporation, where he served as
 President and Chief Executive Officer since December 2002. Brian Lenz, the
 Company's Chief Financial Officer, will serve as interim Chief Executive
 Officer until November 21.
     While at Cytogen, Mr. Becker led the company's transformation from a
 research-driven biotechnology company into a product-focused specialty
 pharmaceutical company with a growing commercial presence in the U.S.
 oncology market. During his tenure he played a critical role in securing
 more than $100 million in new capital for Cytogen.
     "The Board of Directors is pleased to welcome Michael Becker as
 President and Chief Executive Officer of VioQuest. We believe his
 impressive leadership skills, business development accomplishments,
 industry expertise, and successful capital raising track record make him
 the ideal candidate for the job. Further, we have great confidence that
 Michael's experience leading a company focused on the treatment and
 supportive care of cancer patients will prove valuable as we work to better
 leverage our existing asset base and advance new strategic initiatives to
 accelerate growth and build sustainable value," said Stephen Rocamboli,
 Chairman of VioQuest.
     Mr. Becker stated, "I am excited to assume leadership of VioQuest - an
 organization that I believe holds an exceptional amount of growth
 potential. Coming from a specialty pharmaceutical company with a growing
 presence in the U.S. oncology market, I intend to apply my experience to
 ensure that we fully capitalize on VioQuest's solid asset base through
 effective communications with the marketplace, high-quality clinical
 development initiatives, and selective strategic transactions designed to
 accelerate growth. I thank the Board for this opportunity."
     Prior to his most recent role at Cytogen, Mr. Becker progressed through
 positions of increasing responsibility, including Chief Executive Officer
 of AxCell Biosciences, a subsidiary of Cytogen focused on signal
 transduction pathways, and Vice President of Business Development and
 Industry Relations. Prior to joining Cytogen, Mr. Becker was with Wayne
 Hummer Investments LLC, a Chicago-based regional brokerage firm from July
 1996 to April 2001, where he held senior positions as a biotechnology
 analyst, investment executive and portfolio manager. Mr. Becker is Chairman
 of BioNJ, which was founded in 1994 by New Jersey biotechnology industry
 CEOs to serve as the voice of and advocate for the biotechnology industry
 in New Jersey. Mr. Becker is also a member of the Governing Body of
 Biotechnology Industry Organizations (BIO) Emerging Companies Section.
     About VioQuest Pharmaceuticals
     VioQuest focuses on acquiring, developing, and commercializing targeted
 late preclinical and early clinical stage therapies with unique mechanisms
 of action primarily for oncology and infectious diseases. VioQuest has
 three targeted drug candidates in clinical development: VQD-002 which
 inhibits activation of Akt that is seen at abnormally high levels in
 breast, ovarian, colorectal, pancreatic, and hematologic cancers;
 Lenocta(TM), an inhibitor of specific protein tyrosine phosphatases
 (PTPases), SHP-1 and SHP-2, which has shown compelling clinical and
 biological activity in solid tumors and Xyfid(TM), a topical therapy which
 has shown early clinical promise in the treatment and prevention of
 chemo-induced Hand-Foot Syndrome (HFS). VioQuest anticipates commencing
 Phase II trials for VQD-002, Lenocta(TM) and Xyfid(TM) in the first half of
 2008. In addition, VioQuest and the U.S. Army are planning to submit a New
 Drug Application (NDA) to the U. S. Food and Drug Administration (FDA) in
 2008 for Lenocta(TM) for the treatment of leishmaniasis.
     Further information about VioQuest can be found at
 www.vioquestpharm.com.
     This press release contains forward-looking statements that involve
 risks and uncertainties that could cause VioQuest's actual results and
 experiences to differ materially from the anticipated results and
 expectations expressed in these forward-looking statements. These
 statements are often, but not always, made through the use of words or
 phrases such as anticipates, expects, plans, believes, intends, and similar
 words or phrases. These statements are based on current expectations,
 forecasts and assumptions that are subject to risks and uncertainties,
 which could cause actual outcomes and results to differ materially from
 these statements. In addition, this press release also includes
 forward-looking statements regarding the timing, progress and results of
 the clinical development, regulatory processes, potential clinical trial
 initiations, potential IND and NDA filings and commercialization efforts of
 VioQuest's drug development product candidates. These statements are
 subject to various risks and uncertainties and include the possibility that
 the results of clinical trials will not support VioQuest's claims, the
 possibility that VioQuest's development efforts relating to its product
 candidates, including Lenocta(TM), VQD-002, and Xyfid(TM) will not be
 successful, the inability to obtain regulatory approval of VioQuest's
 product candidates, VioQuest's reliance on third-party researchers to
 develop its product candidates, its lack of experience in developing and
 commercializing pharmaceutical products, and the possibility that its
 licenses to develop and commercialize its product candidates may be
 terminated. Additional risks are described in VioQuest's Annual Report on
 Form 10-KSB for the year ended December 31, 2006. VioQuest assumes no
 obligation and does not intend to update these forward-looking statements,
 except as required by law.
     Contact
 
     Brian Lenz, Interim Chief Executive Officer and Chief Financial Officer
     908-766-4400 ext. 117
     brian.lenz@vioquestpharm.com
 
     Lisa Lindberg, Vice President of Investor Relations and Corporate
     Communications
     908-766-4400 ext. 116
     lisa.lindberg@vioquestpharm.com
 
 

SOURCE VioQuest Pharmaceuticals